**Tool Summary Sheet:**

**NIDCR Medical Monitor Oversight Report Template**

**Purpose**: MS Word template to be used as a starting point for preparing an oversight report for Medical Monitor review

**Audience/User**

Statisticians and/or Principal Investigators responsible for preparing NIDCR Oversight Reports for Medical Monitor review

**Details**

This template includes a proposed structure for the oversight report as well as draft language and other guidance.

Completed reports should be submitted to NIDCR via CROMS by email at NIDCR\_Reports@rhoworld.com.

**Best Practice Recommendations**

* Review this template several months prior to the first report due date, and customize to the specific needs and requirements of the study.
* In the template, the instructions and explanatory text are indicated by *{blue italics}* (“CROMS\_Instruction” style). Instructional text will also be enclosed in braces to signify this text for screen-readers used by the visually impaired.
* Text enclosed with <> is a placeholder for a specific detail (e.g., <protocol title>); replace as appropriate.
* Delete template-specific *instructional text* as well as this Tool Summary Sheet during the report development process.
* Leave the template version information in the lower left hand corner of the document.
* It is easiest and cleanest to use the styles that are embedded in the document, rather than to create your own.
* Ensure that all placeholder and example text is replaced with the study specific information.
* If you have questions regarding how your study should be presented in this template, please contact your Program Official, Medical Monitor, or OCTOM.
* Submit your finalized report to NIDCR via CROMS by email at NIDCR\_Reports@rhoworld.com. CROMS will provide the report to the NIDCR Medical Monitor for review and advise your Program Official and OCTOM of its status.

**Tool Revision History:**

|  |  |  |
| --- | --- | --- |
| **Version Number** | **Version Date** | **Summary of Revisions Made:** |
| 1.0 | 16Aug2013 | First approved version |
| 2.0 | 18Nov2013 | Revised document name and added Quality Management / Monitoring sections |
| 3.0 | 15May2017 | Added submission instructions to TSS, added grant # to cover page, and reformatted Section 3 sample enrollment/retention tables. Created a Safety Management and Reporting section as a heading for subsections: UPs, SAEs, AEs, and PDs.  |

**NIDCR medical Monitor OVERSIGHT Report**

**FOR CLINICAL STUDIES**

|  |  |
| --- | --- |
| Protocol Title: | <Insert title of the protocol> |
| Protocol Number: | <Insert protocol number> |
| Principal Investigator(s): | <Name of PIPI’s TitleInstitutionAddress> |
| GRANT NUMBER:  | <Insert grant number> |
|  date Report is due: | <Insert date report is due> |
| Date REport Issued: | <Insert date that the report is being issued> |
| Data Cutoff Date: | <Insert the date of the data snapshot for the analyses in this report> |
| Date of last data report: | <Insert date of last report due>  |
| prepared by: | <Name of person who prepared the reportPerson’s Title / RolePlace of employmentAddress> |

Table of Contents

{This table uses the Table of Contents function in Microsoft Word that will automatically update headings and page numbers used in the body of the report. In the body of the report, add, delete, or modify headings as needed in order to best reflect your study.}

[Protocol Synopsis 5](#_Toc482801010)

[Executive Summary 6](#_Toc482801011)

[1.0 Report Overview 8](#_Toc482801012)

[2.0 Study Objectives and Timeline 8](#_Toc482801013)

[3.0 Enrollment and Retention Status 9](#_Toc482801014)

[4.0 Participant Status 12](#_Toc482801015)

[5.0 Status of Outcome Measures 12](#_Toc482801016)

[6.0 Biospecimen Status 13](#_Toc482801017)

[7.0 Safety Management and Reporting 14](#_Toc482801018)

[7.1 Unanticipated Problems 14](#_Toc482801019)

[7.2 Serious Adverse Events 15](#_Toc482801020)

[7.3 Adverse Events 15](#_Toc482801021)

[7.4 Protocol Deviations 15](#_Toc482801022)

[8.0 Quality Management / Monitoring Findings 15](#_Toc482801023)

[9.0 Study Challenges and Solutions 16](#_Toc482801024)

[Appendix A: Additional Summary Tables 17](#_Toc482801025)

[Appendix B: Additional Figures 18](#_Toc482801026)

[Appendix C: Additional Data Listings 19](#_Toc482801027)

Protocol Synopsis

|  |  |
| --- | --- |
| Protocol Title | <Insert protocol title> |
| Principal Investigator | <Insert name of Principal Investigator> |
| Specific Study Aims | <List specific aims of the study> |
| Study Design | *{Describe study design using the criteria below. Refer to ClinicalTrials.gov* [*http://prsinfo.clinicaltrials.gov/definitions.html*](http://prsinfo.clinicaltrials.gov/definitions.html) *for additional information on data element definitions.}* |
| * **Study Model**
 | *{What is the primary strategy for participant identification and follow-up? Select which best fits the study structure: cohort, case-control, case-only, case-crossover, ecological or community study, family-based, or other (explain). Include number of study groups or cohorts.}* |
| * **Outcome Measures**
 | *{Specify primary and/or secondary outcome measurement(s) or observation(s) used to describe the patterns of disease, traits or associations with exposures or risk factors which are the focus of the study. If appropriate to study design, you may wish to include independent and dependent study variables.}* |
| * **Time Perspective**
 | *{What is the temporal relationship between the observation period and time of participant enrollment? Is the study prospective, retrospective, cross-sectional or other (explain)?}* |
| * **Enrollment**
 | *{What is the participant target enrollment - per site and study total?}*  |
| * **Inclusion Criteria**
 | <List inclusion criteria> |
| * **Exclusion Criteria**
 | <List exclusion criteria> |
| * **Intervention**
 | *{Describe intervention if there is an intervention}* |
| * **Biospecimens**
 | *{List each type of biospecimen (e.g., saliva, fixed/frozen tissue, and/or plasma) to be or being collected. Indicate the purpose for each sample type (e.g., Saliva is being collected for DNA extraction.). Will biospecimen be retained for future research?}* |
| Study Sites | <List name of each study site> |
| Study Activation Date | <Insert activation date of first site> |
| Planned Accrual Period | <Insert time (months, years, etc.)> |
| Planned Duration | <Insert time from first participant-first visit to last participant-last visit (months, years, etc.)> |

Executive Summary

|  |  |
| --- | --- |
| **Study Site Status** | {Example text:}Two of the three study sites have started recruitment. The third will start this month. |
| **Enrollment and Retention Status** | {Include number enrolled and percent of target enrollment. If appropriate, include the same information for retention. Specify study groups, if relevant, (e.g., case-control or adult-child). Summarize here; more detailed information provided in Section 3.0.Example text:} 276 participants, 176 cases and 100 controls, have been enrolled (55% of target enrollment) with 100% retention at 6 months.  |
| **Status of Outcome Measures and Biospecimens** | {Briefly summarize status of biospecimens and key outcome measures. More detailed information provided in Sections 5.0 and 6.0. Example text:} Key outcome measures were collected from 98% of enrollees; 99% meet quality control standards. Details are provided in Section 5.0. |
| **Major Protocol Changes Since Last Report** | {Specify yes or no. If yes, briefly describe major protocol changes and why such changes occurred.} |
| **Safety Management and Reporting (UPs, SAEs, AEs, and PDs)** | {Summarize here; more detailed information provided in Section 7.0. (UPs, SAEs, AEs, and PDs) Example text:} No unanticipated problems (UPs) or serious adverse events (SAEs) have occurred.Three protocol deviations associated with five participants have been reported. Deviations did not affect participant safety. |
| **Quality Management / Monitoring**  | {Provide frequency and dates of Quality Management/Monitoring activities; more detailed information provided in Section 8.0.Example text:} Quality management reviews are performed quarterly and were last completed on July 8, 2013 and October 7, 2013. |
| **Identified Study Challenges and Solutions** | {Summarize challenges encountered thus far in the study. Identify measures taken to address issues. Note any actions taken or solutions from challenges identified in previous reports. More detailed information provided in Section 9.0.} |

{Place summary tables, listings, and figures within the body of the report; however, if the tables, listings, or figures are long, place them in the Appendices. For small numbers of participants, listings may be more appropriate than summary tables.}

# Report Overview

{Provide introductory information. Example:}

The purpose of this report is to review major protocol changes and cumulative enrollment data for the participants enrolled in ‘Study Title’. This report reflects data from the study database as of <date>. Included are summary tables of enrollment, status of clinical biospecimens collected at each site, status of samples processed from the biospecimens, and unanticipated problems (UPs). Additional tables, listings, and figures referenced in this report are provided in Appendices A-C. Past report for the Medical Monitor was provided on June 10, 2013. Participants have been enrolled at 100% and 75% of targeted enrollment at Sites A and B respectively. Updated enrollment details have been provided in Section 3.0. Readers of this report are asked to maintain the confidentiality of the information provided in this report.

# Study Objectives and Timeline

{Describe key study objectives. Highlight any major changes since last NIDCR Medical Monitor Oversight Report was submitted.

Provide a timeline of the study’s principal target components, e.g., current status of recruitment/enrollment (using study specific parameters), biospecimen processing and testing, and data analyses as compared to original or previous projected timeline. This may be provided as a summary, a table of study milestones, or other graphic depiction, as appropriate.

Example of timeline:

***Table # Study Milestones Timeline - July 30, 2012***

| *Milestones* | *Projected Date* | *Status* | *Completion or Revised Projected Date* |
| --- | --- | --- | --- |
| *Recruitment*  |  |  |  |
| *Cases* |  |  |  |
| *50%* | *5.1.2012* | *50% Enrolled* | *4.15.2012* |
| *100%* | *8.1.2012* | *75% Enrolled* |  |
| *Controls* |  |  |  |
| *50%* | *5.1.2012* | *Delayed: 30% Enrolled\** | *7.1.2012\** |
| *100%* | *8.1.2012* |  | *10.1.2012\** |
| *Lab Biospecimen* |  |  |  |
| *100% DNA Processed* | *11.1.2012* | *50% Completed* |  |
| *Analyses* |  |  |  |
| *Genotyping for GWAS* | *12.1.2012* |  |  |
| *GWAS Analysis* | *2.1.2013* |  |  |
| *Whole Exome Sequencing* | *3.1.2013* |  |  |
| *Sequencing Analysis* | *5.1.2013* |  |  |

*Notes:*

*\*By 4.1.2012, only 10% targeted numbers of control participants had been recruited. Projected dates for recruitment of 50% and 100% control participants will be revised to 7.1.2012 and 10.1.2012, respectively. See Section 3.0 below for details.}*

# Enrollment and Retention Status

{Describe enrollment and provide a summary table. Include key study characteristics and relevant study groups (e.g., case-control status, adult-child, race/ethnicity breakdown). Provide enrollment statistics by site if the study involves multiple sites. If the study is enrolling, provide the recruitment target and estimated time to completion of enrollment. A figure showing expected/planned versus actual enrollment is helpful but not required.

Examples: May be study specific (below) or you may use the gender minority tracking table.

***Table # Cases - Enrollment***

| *Cases* | *Site 1* | *Site 2* | *Total* | *% of Target* |
| --- | --- | --- | --- | --- |
| *Target Number to Consent*  | *175* | *125* | *300* |  |
| *Number Consented* | *73* | *48* | *121* | *40.3%* |
|  |  |  |  |  |
| *Target Number to Enter the Study* | *150* | *100* | *250* |  |
| *Number Entered* | *59* | *38* | *97* | *38.8%* |
| *Number Completed* | *16* | *11* | *27* | *10.8%* |
| *Number Discontinued Early* | *2* | *0* | *2* | *0.8%* |
|  |  |  |  |  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| *Entered Population – Totals**Cases* | *Site 1* | *Site 2* | *Total* | *Target Enrollment* | *% of Target Enrollment* |
|  | *59* | *38* | *97* | *250* | *38.8%* |
|  |  |  |  |  |  |
|  *Gender* |  |  |  |  |  |
|  *Female* | *37* | *21* | *58* | *125* | *46.4%* |
|  *Male* | *22* | *17* | *39* | *125* | *31.2%* |
|  *Race* |  |  |  |  |  |
|  *African American* | *25* |  *15* | *40* | *100* | *40.0%* |
|  *Asian* | *8* | *3* | *11* | *50* | *22.0%* |
|  *Caucasian* | *26* | *20* | *46* | *100* | *46.0%* |
|  *Hispanic/Latino ethnicity* |  |  |  |  |  |
|  *Yes* | *12* | *9* | *21* | *65* | *32.3%* |
|  *No* | *47* | *29* | *76* | *185* | *41.1%* |

***Table # Controls - Enrollment***

| *Controls* | *Site 1* | *Site 2* | *Total* | *% of Target* |
| --- | --- | --- | --- | --- |
| *Target Number to Consent*  | *175* | *125* | *300* |  |
| *Number Consented* | *85* | *63* | *148* | *59.2%* |
|  |  |  |  |  |
| *Target Number to Enter the Study* | *150* | *100* | *250* |  |
| *Number Entered* | *68* | *49* | *117* | *46.8%* |
| *Number Completed* | *28* | *19* | *47* | *18.8%* |
| *Number Discontinued Early* | *2* | *1* | *3* | *1.2%* |
|  |  |  |  |  |

| *Entered Population – Totals**Controls* | *Site 1* | *Site 2* | *Total* | *Target Enrollment* | *% of Target**Enrollment* |
| --- | --- | --- | --- | --- | --- |
|  | *68* | *49* | *117* | *250* | *46.8%* |
|  |  |  |  |  |  |
| *Gender* |  |  |  |  |  |
| *Female* | *29* | *18* | *47* | *125* | *37.6%* |
| *Male* | *39* | *31* | *70* | *125* | *56.0%* |
|  *Race* |  |  |  |  |  |
| *African American* |  *28* |  *7* | *35* | *100* | *35.0%* |
| *Asian* |  *6* | *13* | *19* | *50* |  *38.0%* |
| *Caucasian* | *34* | *29* | *63* | *100* | *63.0%* |
| *Hispanic/Latino ethnicity* |  |  |  |  |  |
| *Yes* | *18* | *11* | *29* | *65* | *44.6%* |
| *No* | *50* | *38* | *88* | *185* | *47.6%* |

***Figure #. Expected versus Actual Accrual***

}

# Participant Status

{As relevant to the study design, describe where participants are in the study in relation to major milestones, such as the number who have completed the baseline visit, year 1 follow-up, and the final study visit. A summary table providing the study milestones and the number of participants who have completed those milestones is recommended. Also, provide the number of participants who completed the protocol or discontinued participation and why they discontinued participation (e.g., voluntary withdrawal, lost to follow-up, unanticipated problem, death).

Examples:

***Table # Participant Status, 2011-2012***

|  | *Site 1* | *Site 2* | *Total* |
| --- | --- | --- | --- |
| *Completed visit* | *38* | *30* | *68* |
| *Withdrawn after visit* | *4* | *3* | *7* |

***Table # Participant Status, 2011-2012***

|  | *Site 1* | *Site 2* | *Total* |
| --- | --- | --- | --- |
| *Pregnancy visit* | *38* | *30* | *68* |
| *Birth* | *38* | *30* | *68* |
| *Follow-up visits* |  |  |  |
|  *Visit 1* | *36* | *28* | *64* |
|  *Visit 2* | *36* | *27* | *63* |
| *Withdrawn* | *1* | *1* | *2* |
| *Lost to follow-up* | *1* | *1* | *2* |
| *Discontinued by Study PI* | *0* | *1* | *1* |

 *}*

# Status of Outcome Measures

{Provide information regarding the collection status of outcome measures as described in the Study Design section of the PROTOCOL SYNOPSIS. For data analysis critical to the study’s aims, indicate the status of data collection and quality metrics, as appropriate.

*Example:*

***Table # Number and Percentage of Participants (N/%)***

 ***With Missing Data***

|  | *Site 1* | *Site 2* | *Study Totals* |
| --- | --- | --- | --- |
| *Outcome 1* | *1/0.7%* | *0* | *1/0.3%* |
| *Outcome 2* | *3/2.3%* | *2/1.3%* | *5/1.8%* |
| *Covariate 1* |  *2/1.5%* | *0* | *1/0.7%* |
| *Covariate 2* | *4/3%* | *2/1.3%* | *5/1.8%* |

 *}*

# Biospecimen Status

*{Briefly describe the overall biospecimens testing and analysis plan. For biospecimen collection and analysis critical to the study’s aims, indicate biospecimen status as appropriate.}*

[ ]  Biospecimens being collected

*{State the type of biospecimens collected, status of biospecimen collection and processing, number of samples tested, and quality metrics as appropriate.*

*Example:*

***Table # Biospecimen Status***

|  | *Site 1* | *Site 2* | *Study Totals* |
| --- | --- | --- | --- |
| *Saliva for DNA* |  |  |  |
| *Number of participants with biospecimen(s) collected* |  |  |  |
| *Number of biospecimens tested* |  |  |  |
| *Average DNA quantity* |  |  |  |
| *#/% biospecimens passing DNA quality metrics* |  |  |  |
| *Serum* |  |  |  |
| *Number of participants with biospecimens collected* |  |  |  |

*}*

[ ]  Laboratory analyses {e.g., genotyping, DNA sequencing} underway

 Anticipated completion date: \_\_\_\_\_\_\_\_\_\_\_\_\_

[ ]  Laboratory analyses {e.g., genotyping/sequencing} completed

{Describe quality metrics as relevant, such as number/percent of run failures, average sequence coverage, call rate.}

# Safety Management and Reporting

## Unanticipated Problems

{Summarize or list all unanticipated problems (UPs). Identify measures taken to address them including any protocol changes.

The Office for Human Research Protections (OHRP) considers unanticipated problems, in general, to include any incident, experience, or outcome that meets all of the following criteria:

1. Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described in the protocol-related documents, such as the IRB approved research protocol and informed consent document, and (b) the characteristics of the participant population being studied;

2. Related or possibly related to participation in the research (in this guidance document, possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research); and

3. Suggests that the research places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.

OHRP notes that an incident, experience, or outcome that meets the three criteria above generally will warrant consideration of substantive changes in the research protocol or informed consent process/document or other corrective actions in order to protect the safety, welfare, or rights of participants or others.

Describe any UPs that also meet the definition of SAEs.}

## Serious Adverse Events

{Summarize or list all serious adverse events (SAEs). Identify measures taken to address them including any protocol changes.

An SAE is an AE that meets one or more of the following criteria:

* Results in death
* Is life-threatening (places subject at immediate risk of death from the event as it occurred)
* Results in inpatient hospitalization or prolongation of existing hospitalization
* Results in a persistent or significant disability or incapacity
* Results in a congenital anomaly or birth defect

In addition, an important medical event that does not meet these criteria may be considered an SAE when, based upon appropriate medical judgment:

* the event may jeopardize the subject, and
* may require medical or surgical intervention to prevent one of the previously listed serious outcomes}

## Adverse Events

{Summarize or list all adverse events (AEs) if applicable for the study. Identify measures taken to address them including any protocol changes.

An adverse event is any untoward medical occurrence associated with the participation in clinical research, whether or not study related.}

## Protocol Deviations

{Summarize or list all protocol deviations that have occurred since the previous MMOR and over the course of the study. Identify measures taken to address them including any protocol changes.}

# Quality Management / Monitoring Findings

{Provide details regarding quality management and/or monitoring activities completed since the last Medical Monitor Review, including frequency.  Summarize or list findings and identify measures or corrective actions taken to address the findings or issues that were identified through quality management activities and or on-site monitoring visits.}

# Study Challenges and Solutions

{Summarize issues noted during this study since the last Medical Monitor Review and identify measures used to address them including any protocol changes. In this section, also follow-up on study challenges and solutions identified in previous reports. Examples of study challenges include staffing (turnover) and issues with recruitment.}

**Table <#> Study Challenges and Solutions from Previous Reports**

|  |  |
| --- | --- |
| *Study Challenges* | *Solutions* |
|  |  |
|  |  |

**Table <#> Study Challenges and Solutions New for this Reporting Period**

|  |  |
| --- | --- |
| *Study Challenges* | *Solutions* |
|  |  |
|  |  |

Appendix A: Additional Summary Tables

{It is likely that these Appendices will originate as separate electronic files created by SAS or some other statistical software. If you are creating an electronic version of the full report, use Adobe pdf (or equivalent) to combine the files with this document in a “published” Adobe report. It is very useful to include a Table of Contents or, at a minimum, a list of items contained within each Appendix (e.g., a list of table numbers and names).

Page numbering of the contents of the Appendices are at the discretion of the document owner. Each Appendix file can 1) begin at page 1, or 2) can be numbered contiguously with this document. The second option is advantageous but more difficult to achieve.

A subset of these items may also have been inserted into the report. It is acceptable to also include those items in the corresponding appendix. All other displays that are not inserted into the body of the report should be included herein. It is good practice to ensure that all post-text displays are referenced somewhere in the body of the report.

Include post-text Summary Tables here.}

Appendix B: Additional Figures

{Include post-text Figures here.}

Appendix C: Additional Data Listings

{Include post-text Data Listings here.}